AHS淋巴瘤干细胞移植

1、AHS淋巴瘤干细胞移植,自体造血干细胞移植治疗 恶性淋巴瘤应用进展,AHS淋巴瘤干细胞移植,AHS淋巴瘤干细胞移植,AHS淋巴瘤干细胞移植,Indications for Hematopoietic Stem Cell Transplants in the United States, 2010(Inflation factor: Auto=1.25 (80%), Allo=1.05 (95%), All Transplants),SUM12_28.ppt,Slide 8,Number of Transplants,中山大学肿瘤医院 2020/9/25 星期五 2020/9/25 星期五,AH

2、S淋巴瘤干细胞移植,1. HL,霍奇金淋巴瘤,AHS淋巴瘤干细胞移植,HL :ASCT 综合治疗效果,复发/耐药 ： CR 34-80 % 长期生存率： 25- 50% 早期死亡率 ：421 复发/耐药 ： 10年生存率：50% 10y PFS： 45% 10y RFS： 23% 首次复发： 5年PFS 30 52%, 5年生存率： 3460,中山大学肿瘤医院 2020/9/25 星期五 2020/9/25 星期五,AHS淋巴瘤干细胞移植,复发难治HL PET/CT结果与自体移植的疗效关系,Haematologica 2012,PET/CT -,PET/CT +,中山大学肿瘤医院 2020/9

3、/25 星期五 2020/9/25 星期五,AHS淋巴瘤干细胞移植,复发难治HD :不同预处理方案比较,AHS淋巴瘤干细胞移植,1998-2009 100 pts BuMelTt(busulfan, melphalan,thiotepa): 60pts Others:40pts CBV(21) TBICyE(14) BEAM(4) Melphalan(1) 5 yr-OS 73% VS. 44% 5 yr-PFS 66% VS. 37% No differences in toxicity and NRM,Improved outcome with busulfan, melphalan an

4、d thiotepa conditioning in AHSCT for relapsed/refractory HL,Tarunpreet B. Leukemia 55(3): 583587,PFS,OS,P=0.03,P=0.05,中山大学肿瘤医院 2020/9/25 星期五 2020/9/25 星期五,AHS淋巴瘤干细胞移植,2. NHL, DLBCL弥漫大B淋巴瘤,复发NHL:自体移植是标准治疗手段 PARMA 随机对照研究,OS,PFS,中山大学肿瘤医院 2020/9/25 星期五 2020/9/25 星期五,AHS淋巴瘤干细胞移植,美罗华治疗后复发：AHSCT价值， 2nd,AHS

5、淋巴瘤干细胞移植,Rituximab + DHAP and ASCT 复发DLBCL,Edo Vellenga et al, blood,2008 111: 537-543,DHAP112 73 40 19 9 R-DHAP113 76 55 31 14,R-DHAP,DHAP,Cumulative percentage,Overall survival,AHS淋巴瘤干细胞移植,CORAL研究： 移植后疗效 EFS,Failure from diagnosis = 12 months,Failure from diagnosis 12 months,Failure from diagnosis

6、 = 12 months,Standard salvage regimen does not overcome poor prognosis of early relapse,中山大学肿瘤医院 2020/9/25 星期五 2020/9/25 星期五,AHS淋巴瘤干细胞移植,Rituximab-化疗复发：自体移植的疗效,Br J Haematol.2014 Mar;164(5):668-74 . 有研究提示，美罗华化疗后复发患者自体移植效果差？ 移植后 5年 R+ vs R- PFS 63% 48% OS 72% 61% 美罗华治疗后不会影响移植效果,中山大学肿瘤医院 2020/9/25 星期五

7、 2020/9/25 星期五,AHS淋巴瘤干细胞移植,弥漫大B淋巴瘤：一线,中山大学肿瘤医院 2020/9/25 星期五 2020/9/25 星期五,AHS淋巴瘤干细胞移植,美罗华之前：ASHCT DLBCL 1st,Advances in Hematology, 2012 意大利,AHS淋巴瘤干细胞移植,DLBCL一线治疗: HDCT试验的荟萃分析,Greb et al., 2007, Cancer Treat Rev,中山大学肿瘤医院 2020/9/25 星期五 2020/9/25 星期五,AHS淋巴瘤干细胞移植,美罗华时代：自体移植疗效，1st,Advances in Hematolog

8、y, 2012 意大利,AHS淋巴瘤干细胞移植,自体移植+/-rituximab 治疗初治高危弥漫大BNHL，III期随机对照,OS,EFS,Annals of Oncology Advance Access published May 5, 2010,AHS淋巴瘤干细胞移植,Dose-dense and high-dose chemotherapy plus rituximab + ASHSCT for primary treatment of DLBCLwith a poor prognosis: a phase II multicenter study,R-HDC,HDC,R-HDC,H

9、DC,haematologica | 2009; 94(9),R-HDC,HDC,HDC,R-HDC,AHS淋巴瘤干细胞移植,SWOG-9704 研究设计,Stiff P, et al. N Engl J Med 2013; 369(18):1681-1690.,AHS淋巴瘤干细胞移植,SWOG-9704 显示：移植组较对照组显著延长2年PFS，但是OS上无差别,Stiff P, et al. N Engl J Med 2013; 369(18):1681-1690.,AHS淋巴瘤干细胞移植,SWOG-9704亚组分析显示：移植组在aaIPI为3分的患者中可以较对照组明显延长患者PFS,Sti

10、ff P, et al. N Engl J Med 2013; 369(18):1681-1690.,AHS淋巴瘤干细胞移植,SWOG-9704亚组分析显示：移植组在aaIPI为3分的患者中可以较对照组明显延长患者OS,Stiff P, et al. N Engl J Med 2013; 369(18):1681-1690.,AHS淋巴瘤干细胞移植,原发中枢淋巴瘤：自体移植价值HD AraC +VP16(CYVE)+HDCT(TT-BU-CY)as salvage for relapse/resistant PCNSL,2011 update N=60, median FU 5y OS che

11、mosensitive 97 m chemoresistant 18 m ICML 2011 Abstr.035,Resp+HDCT,No Resp+HDCT,Resp no HDCT,NO resp no HDCT,中山大学肿瘤医院 2020/9/25 星期五 2020/9/25 星期五,AHS淋巴瘤干细胞移植,继发中枢 淋巴瘤 移植效果 好！,AHS淋巴瘤干细胞移植,化疗敏感 62% vs 不敏感36.2%,Thiotepa, busulfan and cyclophosphamide + AHSCT ，复发难治原发中枢淋巴瘤, 5yOS,CR 56.4% vs 未CR 31.1%,Hae

12、matologica.2012 Nov;97(11):1751-6.,AHS淋巴瘤干细胞移植,AHSCT前CR/PR，移植后CR患者（5y-OS 62%） AHSCT前SD/PD，移植后CR患者（5y-OS 38.9%） 移植后未获得CR患者 （5y-OS 31.1%）,Thiotepa, busulfan and CTX + AHSCT for relapsed or refractory PCNSL/PLOT,Haematologica.2012 Nov;97(11):1751-6.,AHS淋巴瘤干细胞移植,2000 至2010 年 27例 中位年龄: 59岁 中位 ECOG评分: 2 7

13、6% DLBCL 中位OS 7月 1年OS：62%,自体移植治疗淋巴瘤继发中枢侵犯 an International Primary CNSL Study Group project,Jacoline E. haematol.2012.070839,AHS淋巴瘤干细胞移植,ASCT ：DLBCL临床资料,70例， 中山大学肿瘤医院 2004.10-2013.3 男性41例，女性29例 中位年龄43岁（21-76岁） 中位随访时间35.5月（0.4-94.2月） 因肿瘤死亡29例,AHS淋巴瘤干细胞移植,DLBCL OS 生存曲线 中山大学肿瘤医院,1年OS 91.0% ,3年OS 77.7%

14、,5年OS 56.9%,AHS淋巴瘤干细胞移植,AHSCT：复发难治老年DLBCL-日本血液学协会回顾性研究，2013ASH,1993-2010年 484pts 中位64岁（60-78） 中位随访26.5月 移植相关死亡 - 4.1% (100天) - 5.9%（1年） - 10.7% 3年） 2年 PFS 48%， OS 58% 60-64,65-69，70岁，移植相关死亡无差异 OS预后因素：70岁，PS 2-4分，移植前未CR Biol Blood Marrow Transplant.2014 Jan 31.,AHS淋巴瘤干细胞移植,100d: 4.1% 1 yr: 5.9% 2 yr:

15、 7.7% 3 yr: 10.7%,复发难治老年弥漫大B淋巴瘤DLBCL: A Nationwide Retrospective Study,Dai Chihara. Biol BMT. 20 (2014) 684-689,1993 to 2010 year Japan Society for HCT database 484 patients median age : 60 years,AHS淋巴瘤干细胞移植,The cumulative risk of relapse 1-yr: 38.8% 2-yr: 45.5% 3-yr: 47.7% Multivariate analysis 70y

16、 PS 2 to 4 at ASCT not in remission at ASCT,High-Dose Chemotherapy with ASCT for Elderly Patients with Relapsed/Refractory DLBCL: A Nationwide Retrospective Study,Dai Chihara. Biol BMT. 20 (2014) 684-689,AHS淋巴瘤干细胞移植,1-yr: 55.9% 2-yr: 47.7% 3-yr: 40.6%,1-yr: 69.7% 2-yr: 57.9% 3-yr: 49.6%,Dai Chihara.

17、 Biol BMT. 20 (2014) 684-689,High-Dose Chemotherapy with ASCT for Elderly Patients with Relapsed/Refractory DLBCL: A Nationwide Retrospective Study,AHS淋巴瘤干细胞移植,High-Dose Chemotherapy with ASCT for Elderly Patients with Relapsed/Refractory DLBCL: A Nationwide Retrospective Study,2-yr OS 6064 64.6% 65

18、69 50.6% 70y 45.7%,Dai Chihara. Biol BMT. 20 (2014) 684-689,AHS淋巴瘤干细胞移植,Zevaline + BEAM: DLBCL 1st line,2011 lugano abs 256, GELA ,法国 75 DLBDL, R-CHOP/ R-ABVCP IPI 1 1;IPI 2 27; IPI 3-5 47 F/U 23m, 2y EFS 74%, 2y OS 80.5% PET +/- before AHSCT: same 1 toxic death promising with acceptable toxicity.,A

19、HS淋巴瘤干细胞移植,Zevalin +BEAM vs BEAM AHSCT for Aggressive Lymphoma,43 CD20+ pts 中位年龄55岁 病理类型 - DLBCL - transformed FL,Zevalin+BEAM N=22,BEAM N=21,R,AHSCT,Z-BEAM - Rituximab 250 mg/m2 - Zevalin 0.4 mCi/kg d -14 - Carmustine 300 mg/m2 d -6 - Etoposide 200 mg/m2 d -5 - -2 - Cytarabine 200 mg/m2 Q12h d -5 -

20、 -2 - Melphalan 140 mg/m2 d -1,Cancer.2012 Oct 1;118(19):4706-14,AHS淋巴瘤干细胞移植,2y-OS:91% VS 62%(P=0.05),Zevalin +BEAM vs BEAM AHSCT for Aggressive Lymphoma,2y-PFS: 59% VS 37%(P=0.2),Cancer.2012 Oct 1;118(19):4706-14,AHS淋巴瘤干细胞移植,23 pts without CR to salvage chemotherapy 6 pts RIT combined with HD-chemo

21、therapy 8 pts received a sequential HD- chemotherapy with a second ASCT,Myeloablative Anti-CD20 RIT High-Dose Chemotherapy Followed by ASCT for Relapsed/Refractory B-Cell Lymphoma Results in Excellent Long-Term Survival,Wagner JY. Oncotarget, June, Vol.4, No 6,AHS淋巴瘤干细胞移植,The ORR 87% CR: 64% Median

22、PFS 47.5m Median OS 101.5 months,Myeloablative Anti-CD20 RIT High-Dose Chemotherapy Followed by ASCT for Relapsed/Refractory B-Cell Lymphoma Results in Excellent Long-Term Survival,Wagner JY. Oncotarget, June, Vol.4, No 6,AHS淋巴瘤干细胞移植,(A) OS according to treatment modality (B) PFS according to treatm

23、ent modality,(C) OS RIT VS. RIT/HD-CTX or RIT/BEAM (D) PFS RIT VS. RIT/HD-CTX or RIT/BEAM,Myeloablative Anti-CD20 RIT High-Dose Chemotherapy Followed by ASCT for Relapsed/Refractory B-Cell Lymphoma Results in Excellent Long-Term Survival,Wagner JY. Oncotarget, June, Vol.4, No 6,AHS淋巴瘤干细胞移植,Philippe

24、A. J Clin Oncol 31:4199-4206.,PD-1 Blockade Pidilizumab + AHSCT DLBCL an International Phase II Trial,66例 30 centers in USA 化疗敏感复发 ，Chemotherapy sensitive,66pts,Pidilizumab(PD-1) 1.5 mg/kg3, Q42d 30 to 90d from AHSCT,AHSCT,Restaged at 30, 44, and 69 w,AHS淋巴瘤干细胞移植,OS (16m): 85% PFS(16m): 72%,Disablin

25、g Immune Tolerance by PD-1 Blockade With Pidilizumab After AHSCT for DLBCL: Results of an International Phase II Trial,PFS and OS of all eligible patients,PFS and OS of the 24 eligible patients who PET(+) after salvage therapy,PFS(16m): 70%(PET+) 72%(PET-),Philippe A. J Clin Oncol 31:4199-4206.,中山大学

26、肿瘤医院 2020/9/25 星期五 2020/9/25 星期五,AHS淋巴瘤干细胞移植,3. PTCL-U 外周非特异性,AHS淋巴瘤干细胞移植,复发耐药T-NHL长期随访结果，常规化疗,N=45, 总生存曲线,黄慧强等，2007 癌症,中山大学肿瘤医院 2020/9/25 星期五 2020/9/25 星期五,AHS淋巴瘤干细胞移植,ASCT 治疗外周T淋巴瘤：一线,中山大学肿瘤医院 2020/9/25 星期五 2020/9/25 星期五,AHS淋巴瘤干细胞移植,ASCT 外周T淋巴瘤：复发,AHS淋巴瘤干细胞移植,T-NHL自体干细胞移植随访结果,35 例, 中位随访23个月，预计中位总生

27、存54个月， PTCL-U 17.1%，LBL 42.9%，ALCL20%，NK/T 14.33%，皮下脂膜炎样T 5.7% 1，3，5年OS为71%，59%，46%,中山大学肿瘤医院内科,AHS淋巴瘤干细胞移植,ASHCT 治疗T-NHL(一线/复发),2011 lugano ICML, abs 100 MDACC 美国 126例， 49（18-75），初治33， 预处理：BEAM 4年 OS PFS CR1 87 67 敏感复发 39 36 难治 24 15 PTCLU 42 48 ALCL 47 37 NK/T 6 67 LBL 14 AHSCT 考虑一线应用,AHS淋巴瘤干细胞移植,A

28、utoHSCT vs alloHSCT T-NHL: CIBMTR analysis (19962006),自体，autoHCT (n=115) more in ALCL (53% vs. 40%, p=0.04) less advanced: CR1(35% vs. 14%, p=0.001), chemosensitive disease (86% vs. 60%, p0.0001) 2 lines prior therapy (65% vs. 44%, p0.001) 异基因，alloHCT (n=126, 76 matched siblings),100 d TRM 1yr OS 3y

29、r OS 复发死亡 autoHCT 2% 62% 53% 73% alloHCT 17% 52% 41% 44%,Sonali Smith,et al. ASH2010, Abstract 689.,AHS淋巴瘤干细胞移植,Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma,NRM :non relapse mortality,Sonali M. J Clin Oncol 31:3100-3109.,241pts - ALCL (112) - PTCL-U(102) - AITL(

30、27) 60 yr Lines prior to transplantation - 3(164) - 3(73),autoHCT N=115,Primary outcomes PFS NRM OS,alloHCT N=126,AHS淋巴瘤干细胞移植,OS,PFS,NRM,NRM,PFS,OS,Sonali M. J Clin Oncol 31:3100-3109.,Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma,AHS淋巴瘤干细胞移植,PFS,OS,NRM,PFS,OS,He

31、matopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma,Sonali M. J Clin Oncol 31:3100-3109.,AHS淋巴瘤干细胞移植,P Corradini. Leukemia (2014), 17,Intensified chemo-immunotherapy SCT in newly diagnosed PTCL,AL: alemtuzumab HyperCHidam: - HD-MTX 1.6 g/m2 d1, - CTX 300 mg/m2 Q12h d1-3

32、- HD-Ara-C 2 g/m2 Q12h d1-3,AHS淋巴瘤干细胞移植,P Corradini. Leukemia (2014), 17,Clin A study - 4 yr OS 49% - 4 yr PFS 44% - 4 yr DFS 65%,Intensified chemo-immunotherapy SCT in newly diagnosed PTCL,AHS淋巴瘤干细胞移植,P Corradini. Leukemia (2014), 17,Clin B study - 4 yr OS 32% - 4 yr PFS 26% - 4 yr DFS 44%,Intensif

33、ied chemo-immunotherapy SCT in newly diagnosed PTCL,中山大学肿瘤医院 2020/9/25 星期五 2020/9/25 星期五,AHS淋巴瘤干细胞移植,晚期、复发NK/T 淋巴瘤,AHS淋巴瘤干细胞移植,，自体外周血造血干细胞移植: NKT淋巴瘤，1st,获益患者 CR、 III-IV期 预后不良,（kim HJ,et al. Bone Marrow Transplant. 2006),AHS淋巴瘤干细胞移植,自体移植: III/IV 期和复发难治 NK/T Promising,3-y OS 78.6%13.9% 3-y PFS 63.6% 1

34、4.5%,Huang hui-qiang, et al in press,中山大学肿瘤医院 SYSUCC,P-Gemox CR/PR 自体移植,AHS淋巴瘤干细胞移植,YDM, 女，24岁，IVB NK/T,腹部巨大肿块，PS=2 腹腔肠道广泛受累 1疗程后肠穿孔， 人工肛， PEG-Gemox 6疗程，CR ASCT 后12个月 CCR,AHS淋巴瘤干细胞移植,Upfront Autologuos Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01,5y-OS 51%,5y-PFS 41%,J Clin Onco

35、l.2013 May 1;31(13):1624-30.,中山大学肿瘤医院 2020/9/25 星期五 2020/9/25 星期五,AHS淋巴瘤干细胞移植,4 . FL， 滤泡型淋巴瘤,AHS淋巴瘤干细胞移植,Randomized Trials of Upfront Autologous Transplantation for FL,1. Gyan E, et al. Blood. 2009;113:995-1001. 2. Lenz G, et al. Blood. 2004;104:2667-2674. 3. Sebban C, et al. Blood. 2006;108:2540-25

36、44. 4. Ladetto M, et al. Blood. 2008;111:4004-4013.,AHS淋巴瘤干细胞移植,Long term outcome of AHSCT 复发滤泡型,248 pts, age 47 (20-67) y Median prior chemotherapies 2, 110 pts AHSCT only Median F/U 6 years ( 1-16 ) y 47% progression 13% died without NHL 44% 5Y EFS 63% 5y OS 2005 ASCO ,abstract 6567 J Vose et al U

37、niversity of Nebraska medical center,AHS淋巴瘤干细胞移植,CUP trial: PFS,1.0 0.8 0.6 0.4 0.2 0,012 24 36 48 60 72 84,Months,Proportion progression-free,EventsTotal Chemotherapy2024 Unpurged 922 Purged1124,Schouten H, et al. J Clin Oncol 2003;21:391827,AHS淋巴瘤干细胞移植,Tandem Transplant for，双移植 Follicular NHL60y,3

38、6pts advanced/recurrent FL; previously untreated 26. Treatment: C2H2OP2 Melphalan140mg/m2 CTX120mg/kg+TBI CR(%) 30.6 62.9 94.3 Median F/U 86m. 10y DFS 60% 10y OS 83% Conclusion -tandem transplant is safe and could be curative for selected FL -No correlation between molecular and clinical relapse. Ch

39、ristiam Recher . France 2003 ASH,AHS淋巴瘤干细胞移植,研究流程,复发FL: 移植前利妥昔单抗净化和/或移植后维持EBMT一项前瞻性研究, ASCT,Ruth P. J Clin Oncol 31:1624-1630,AHS淋巴瘤干细胞移植,10 yr PFS: 48.6% vs. 42%(P=0.18),Effect on PFS,10 yr PFS: 54% vs. 37%(P=0.12),是否Rituximab净化,是否Rituximab维持,Ruth P. J Clin Oncol 31:1624-1630,复发FL: 移植前利妥昔单抗净化和/或移植后

40、维持 EBMT一项前瞻性研究, ASCT,AHS淋巴瘤干细胞移植,Sequential therapy with alternating short courses of R-chop and R-FM followed by ASCT results in long term remission in advanced FL,Enrico D. bjh.2014.12894,10 yr OS 87% 10 yr PFS 65% 10 yr OS(treated at disease relapse) 70% 10 yr PFS(treated at disease relapse) 60%,

41、AHS淋巴瘤干细胞移植,Author N F/U PFS (%) OS(%) Foran 29 29 52 (48) 50 (102 ) Friedberg 27 36 46 (60) 58 (60) Williams 50 59 30 (60) 37 ( 60 ) Chen 35 52 31 (60) 37 ( 60 ),移植后远期生存率： PFS:30- 52%, OS 37- 58%,ASCT: 转化滤泡型淋巴瘤,AHS淋巴瘤干细胞移植,转化的惰性淋巴瘤: 自体造血干细胞移植随机对照,105pts 中位年龄：54岁 病理类型： DLBCL(102) 1996-2009年,50(48%)例

42、接受AHSCT,55(52%)例未接受AHSCT,R,AHSCT VP-16 Mephalan TBI,IFRT 30-35Gy (Bulk disease),D. Villa. Annals of Oncology24: 16031609, 2013,AHS淋巴瘤干细胞移植,Overall Survival,Prgression-Free Survival,ASCT vs. No ASCT,ASCT(2005年后) vs. ASCT(2005年前),D. Villa. Annals of Oncology24: 16031609, 2013,转化的惰性淋巴瘤: 自体造血干细胞移植随机对照,A

43、HS淋巴瘤干细胞移植,移植前加用rituximab VS. 移植前未使用rituximab,Overall Survival,D. Villa. Annals of Oncology24: 16031609, 2013,转化的惰性淋巴瘤: 自体造血干细胞移植随机对照,AHS淋巴瘤干细胞移植,High-dose RIT+ + AHCT for poor-risk or relapsed B-cell NHL,No transplant-related death 30 ( 97%) pts engrafted Median follow-up of 21 months (range 1.4-43

44、): 2-year estimated OS 93% 2-year estimated DFS 80% Conclusions The novel High-dose RIT with ZEVALIN + high-dose VP-16 and CY is well tolerated and effective in refractory B-cell NHL,AHS淋巴瘤干细胞移植,Autologous and Allogeneic SCT for Transformed FL: A Report of the Canadian BMT,J Clin Oncol.2013 Mar 20;3

45、1(9):1164-71.,中山大学肿瘤医院 2020/9/25 星期五 2020/9/25 星期五,AHS淋巴瘤干细胞移植,双移植 auto-allo transplant 复发难治滤泡,Biol Blood Marrow Transplant.2012 Jun;18(6):951-7. 27 例， 3 线 随访39 月, OS 96% 3年PFS 96%,AHS淋巴瘤干细胞移植,5 .套细胞淋巴瘤MCL,AHS淋巴瘤干细胞移植,1.套细胞淋巴瘤2008，2009R-CHOP + AHSCT : R-CHOP+ IFN,PFS R-CHOP + AHSCT VS IFN,PFS， R-CHO

46、P + AHSCT VS 其他,AHS淋巴瘤干细胞移植,年轻一线：MCL1 vs MCL 2,AHS淋巴瘤干细胞移植,套细胞淋巴瘤长期随访：MCL2方案,AHS淋巴瘤干细胞移植,360 例患者 2000-2009年 18岁 Multivariate analysis,一项EBMT关于套细胞淋巴瘤移植后复发的预后因素 和生存研究的回顾性分析,S. Dietrich. Annals of Oncology25: 10531058, 2014,AHS淋巴瘤干细胞移植,Median OS: 19m,Relapesd 12m,S. Dietrich. Annals of Oncology25: 1053

47、1058, 2014,一项EBMT关于套细胞淋巴瘤移植后复发的预后因素 和生存研究的回顾性分析,AHS淋巴瘤干细胞移植,First line vs. salvage SCT,OS after ASCT failure by timing of first ASCT,OS after ASCT failure by refractory disease,Sensitive vs. refractory,S. Dietrich. Annals of Oncology25: 10531058, 2014,一项EBMT关于套细胞淋巴瘤移植后复发的预后因素 和生存研究的回顾性分析,AHS淋巴瘤干细胞移植

48、,2000-2003年 vs.2004-2007年,OS after ASCT failure by calendar year of relapse,OS from 3 months landmark after ASCT failure by response to first-salvage regimen given for relapse,CR vs.PR vs. SD/PD,S. Dietrich. Annals of Oncology25: 10531058, 2014,一项EBMT关于套细胞淋巴瘤移植后复发的预后因素 和生存研究的回顾性分析,AHS淋巴瘤干细胞移植,Nordic

49、 MCL3 研究: 90Y-ibritumomab-tiuxetanadded 联合BEAM/C 治疗 移植前未CR的套细胞淋巴瘤,Arne K. Blood. 2014 123: 2953-2959,160pts Untreated Stage II-IV 66 yr,MCL2 6 R-maxi-CHOP R-HD-Ara-C,R E S P O N D I N G,CR,CRu/PR Zevalin1 1w before ASCT Rituximab 250mg/m2 1 w before and just prior to Zevalin,AHSCT BEAM/BEAC,AHS淋巴瘤干细

50、胞移植,EFS OS PFS,Survival curves for MCL2 and MCL3,Nordic MCL3 研究: 90Y-ibritumomab-tiuxetanadded 联合BEAM/C 治疗 移植前未CR的套细胞淋巴瘤,Arne K. Blood. 2014 123: 2953-2959,AHS淋巴瘤干细胞移植,移植前基于PET/CT扫描结果的生存曲线,PFS,OS,Nordic MCL3 研究: 90Y-ibritumomab-tiuxetanadded 联合BEAM/C 治疗 移植前未CR的套细胞淋巴瘤,Arne K. Blood. 2014 123: 2953-2959,AHS淋巴瘤干细胞移植,基于微小病灶残留检测的PFS曲线,移植前,移植后,Nordic MCL3 研究: 90Y-ibritumomab-tiuxetanadded 联合BEAM/C 治疗 移植前未CR的套细胞淋巴瘤,Arne